The major mood disorders, which include bipolar disorder and major depressive disorder (MDD), are considered heritable traits, although previous genetic association studies have had limited success in robustly identifying risk loci. We performed a meta-analysis of five case-control cohorts for major mood disorder, including over 13,600 individuals genotyped on high-density SNP arrays. We identified SNPs at 3p21.1 associated with major mood disorders (rs2251219, P = 3.63 × 10 −8 ; odds ratio = 0.87; 95% confidence interval, 0.83-0.92), with supportive evidence for association observed in two out of three independent replication cohorts. These results provide an example of a shared genetic susceptibility locus for bipolar disorder and MDD.
Counts refer to subjects who passed all quality-control filters (see Online Methods and Supplementary Note).
l e T T e r S
Observed genotypes at rs2251219 were available in all samples except for GAIN-MDD. For that sample, we used imputed genotypes at rs2251219 (Supplementary Table 2 ). The imputation is expected to be highly reliable, as imputation methods perform well in Europeanancestry samples 5 , and there was strong linkage disequilibrium (LD) among the markers flanking rs2251219 (r 2 ≥0.98). One nearby SNP that was genotyped in the GAIN-MDD sample, rs2289247, returned a meta-analysis P-value of 8.96 × 10 −7 , similar to that of rs2251219. Random masking of 5% of genotypes had little effect on the imputation results (data not shown).
The analysis of rs2251219 was repeated under a random-effects model, with similar results (P = 3.62 × 10 −8 ; Supplementary Table 3) . The pooled odds ratio (OR) was 0.87 (95% confidence interval (CI), 0.83-0.92), with no evidence of heterogeneity (Q = 2.93, 3 degrees of freedom, P not significant; I 2 = 0). GAIN-MDD returned a similar OR of 0.90 (95% CI, 0.82-0.99), consistent with a similar contribution of this locus to both bipolar disorder and MDD.
To assess robustness of these association results to the contribution of each individual study, we repeated the analysis five times, removing one sample each time. Randomeffects P-values at rs2251219 ranged from 10 −6 to 10 −9 , reflecting varying sample sizes, but the ORs remained stable (Supplementary Table 3 ). This suggests that the results are not driven by any single sample.
We subsequently obtained association results at rs2251219 in an independent bipolar disorder case-control sample (n = 1,536) genotyped by GlaxoSmithKline (GSK) 6 .
The C allele of rs2251219 was significantly under-represented in bipolar disorder cases compared to controls (P = 0.002, OR = 0.78; Table 2 ), replicating our main meta-analysis result. Data from two independent MDD case-control samples were also obtained from GSK 3 : a clinical sample from Munich (n = 1,792) and a population-based sample from Lausanne (n = 1,349). No significant association with rs2251219 was found in either MDD sample, although in the Munich sample the 95% CI of the OR (0.79-1.03) substantially overlapped with that of the present study (0.83-0.92; Table 2 ). Additional, nearby markers also showed evidence of association in one or more samples (data not shown). When all three samples were combined with our original results, the evidence of association at rs2251219 increased (fixedeffects P = 1.67 × 10 −9 ; random-effects P = 4.99 × 10 −9 ). These data thus provided support for our findings in independent samples, but the findings were more robust in bipolar disorder than in MDD.
The association signals on chromosome 3p spanned a ≥246-kb region containing several annotated transcripts (Fig. 1b) . SNP rs2251219 is a synonymous variant in the gene PBRM1, which encodes polybromo-1, important in chromatin remodeling 7 . The nearby SNP rs2289247 is a nonsynonymous variant in the gene GNL3; this SNP results in a valine-to-methionine substitution in the GTPase nucleostemin, involved in proliferation of stem cells, especially in the central nervous system 8 . These genes are good biological candidates, but the LD across the locus is very strong (r 2 > 0.9; Fig. 1c) , complicating efforts to localize functional marker(s) in individual genes by association mapping alone.
To help prioritize candidate genes in this region for further study, we examined gene expression in brain tissue. PBRM1 was overexpressed in the dorsolateral prefrontal cortex of individuals with l e T T e r S bipolar disorder (P = 0.018; Supplementary Fig. 2 ), compared to that of healthy controls. This finding, not confounded by linkage disequilibrium in the region, independently implicates PBRM1 in bipolar disorder. We also mined two brain expression data sets 9,10 to test 22 disease-associated SNPs for cis association with expression of all known transcripts in the 3p region. Apparent associations between rs2251219 and expression of PBRM1 and GLT8D1 involved probes that overlap common SNPs, an important source of artifact 11 . Neither was confirmed by quantitative PCR in the Stanley Brain Foundation Samples, and the GLT8D1 finding could not be confirmed in cDNA from the original study 9 when probes that did not overlap known SNPs were used (data not shown). This is the first study to report a genome-wide significant association on chromosome 3p to a psychiatric disorder, although previous studies have detected suggestive evidence of association in this region 6, 12 . A meta-analysis of bipolar disorder GWAS in samples that overlap with those in the present study found suggestive signals in this region 6 ; the most significant SNP in that study was nominally significant in the present study (rs1042779; P = 0.001). Considering the strong local LD, all of these studies may have detected signals arising from the same risk allele(s).
Previous major mood disorder GWASs have highlighted several genes elsewhere in the genome. We detected association with most of these genes (Supplementary Table 4 ), but our results are not independent replications since the samples we used overlapped with those in the previous studies. In addition, we did not find a significant association signal at any of these loci after genome-wide correction for multiple testing. Such association results may vary from study to study, owing to limited power to detect the association in each study, differences between the studies and other unmeasured factors. Thus, even this meta-analysis of five large cohorts may be too small or heterogeneous to detect all important risk alleles at genome-wide significance. A larger-scale meta-analysis is expected when the Psychiatric GWAS Consortium 13 completes its study that includes fully imputed data from the samples analyzed here as well as additional cohorts.
Our genetic association results provide support for the previous epidemiologic evidence of genetic overlap between bipolar disorder and MDD 2 . These data do not explain why, among all those carrying risk variants, some develop bipolar disorder, others develop MDD and still others remain apparently healthy. This phenomenon may reflect variation at a larger number of genetic loci, only few of which have been detected to date, environmental influences, and perhaps epigenetic factors.
The genetic association findings so far seem to account for little of the inherited risk for mood disorders. Because GWA studies usually omit SNPs with minor allele frequencies below 3%-5%, we can say nothing about alleles in that frequency range, even if they have relatively strong effects. If rare alleles of large effect exist, each can account for only a small proportion of cases. More common autosomal alleles (frequency >20%) conferring a heterozygote relative risk of 1.3 would have been detected with >90% power in this sample. Many loci may add together to confer risk, as some studies suggest 14, 15 , or fewer loci may interact, but to our knowledge, strong epistasis has not yet been demonstrated in complex human traits. The genetic architecture of the major mood disorders thus seems to be multigenic and/or highly heterogeneous. As robust findings accumulate and sample sizes grow, the identified genes may highlight pathways of etiologic relevance. The GWAS remains an important means to that end, even though each individual finding may represent only a small step forward.
MeThoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. dbGaP: NIMH bipolar disorder sample, phs000017. v1.p1.c1-c3; GAIN major depression sample, phs000020.v1.p1.
Note: Supplementary information is available on the Nature Genetics website.

ACkNoWleDGMeNTS
Genotyping of the GAIN major depression and NIMH bipolar disorder samples was provided through the Genetic Association Information Network (GAIN), Foundation for NIH (the US National Institutes of Health). The data sets used for the analyses described in this manuscript were obtained from the Database of Genotypes and Phenotypes (dbGaP). Samples and associated phenotype data were provided by the contributing studies. We thank the Wellcome Trust Case Control Consortium, the STEP-BD group, the Netherlands Study of Depression and Anxiety and the Netherlands Twin Registry for making data or results available for analysis. This study used the high-performance computational capabilities of the Biowulf Linux cluster at the NIH. oNLINe MeThoDS Study samples. The samples used in the meta-analysis have been described previously [16] [17] [18] [19] . Details, including quality control procedures applied to the genotyping data and a description of the replication samples, are provided in the Supplementary Note. Imputation. Genotype data from the NIMH-BP, GAIN-MDD and German samples were used to impute data on 2.1 million HapMap Phase 2 SNPs by use of the program Markov Chain Haplotyping (MACH), version 1.0 (ref. 20) . MACH uses Markov chain haplotyping to resolve haplotypes, and thereby missing genotypes, from observed genotypes in unrelated individuals. We used the "greedy" algorithm, as recommended by the authors. SNPs that were flagged as having different alleles than in HapMap CEU or as monomorphic were reviewed, after which they were either recoded for the reverse strand (flipped) or dropped. SNPs that were flagged for allele frequencies that were markedly different from HapMap CEU were also reviewed. Palindromic SNPs whose allele frequencies were consistent with reversed coding were flipped. Other SNPs with unexpected allele frequencies were dropped. PLINK 21 (version 1.4) was used to flip and drop SNPs as necessary. After all allele-coding, monomorphism and palindrome issues were resolved, imputation was run again. SNPs in the results files were dropped if the minor allele frequency in cases or controls was <0.05 or if the error rate (as reported in the .erate output file) was >0.01. Finally, the imputed data were formatted into PLINK binaries for analysis.
Meta-analysis. PLINK output (.assoc) files were modified with columns for direction of association, sample size and strand. For most samples, sample size equaled the sum of cases and controls included in the final analysis, after quality control. For the STEP-BD sample, sample size was set to equal the number of cases only. This was done to avoid over-weighting the results from the NIMH control sample, largely overlapping portions of which were included in both the NIMH-BP and STEP-BD samples. Modified files were loaded into Metal (July 2008 version), then processed using the GENOMICCONTROL option, which applies a genomic control 22 correction in samples where the genomic inflation factor is greater than 1.0. Metal weights each sample on the basis of the square root of the sample size.
Care was taken in combining results from different samples and platforms to avoid confusing alleles, especially at palindromic SNPs. To check this, we inspected all SNPs whose range of allele frequencies in the meta-analysis was greater than 0.2, a commonly used threshold. Most of these SNPs were palindromes, and, as expected, their minimum and maximum allele frequencies across the study samples added to ~1. Using the "STRANDLABEL" and "USESTRAND ON" commands in Metal, we corrected these SNPs to ensure consistent allele coding across the samples analyzed. Because the German sample was genotyped on the Illumina platform that contains no palindromic SNPs, we used that sample as the gold standard. A final check identified 36 SNPs whose allele frequency ranges still exceeded 0.2. Most of these were not palindromes, and those that were did not show complementary allele frequencies. We concluded these were unreliable SNPs and dropped them from the analysis.
Selected results were confirmed, and heterogeneity statistics were calculated, using Comprehensive Meta-analysis, version 2.0. This performs a randomeffects meta-analysis that is robust to sample heterogeneity, as well as explicit tests of heterogeneity using Q and I statistics 23 . To account for overlap in control samples, we grouped cases from the NIMH-BP and STEP-BD samples (which do not overlap) and compared them, as a whole, with the controls used in the STEP-BD report, as recommended by some authorities 24, 25 .
We used a threshold of genome-wide significance (7.2 × 10 −8 ) derived from a published, genome-wide simulation of common variants in samples of European ancestry 4 . This threshold is more conservative than the value of 1.6 × 10 −7 that would represent a Bonferroni-corrected P = 0.05 for the ~318,000 markers tested, but is consistent with accepted thresholds for genome-wide significance 26 . Although we set out to find variants shared in common between bipolar disorder and MDD, we have considered only bipolar disorder in other studies 16 . The results at rs2251219 would remain significant even if multiplied by 2 to account for this.
Power analysis. Power analysis was done with Genetic Power Calculator 27 . We assumed a trait prevalence of 2%, a minor allele frequency of 20%, an alpha of 7.2 × 10 −8 and a marker-allele D′ value of 0.8.
Gene expression analysis.
We obtained brain RNA and genomic DNA samples from the Stanley Medical Research Institute (SMRI). This collection comprises three diagnostic groups, each with 35 samples: healthy control, bipolar disorder and schizophrenia. All experiments were done after the specimen code was broken, and they were thus unblinded. RNA samples originated from the dorsolateral prefrontal cortex. Of these, 101 samples provided sufficient RNA for reverse transcription (Transcriptor First Strand cDNA Synthesis kit with oligo(dT) priming, Roche Applied Science) and subsequent real-time PCR analysis. We amplified PBRM1 mRNA with a primer pair common to all known RefSeq transcript variants (Eurofins MWG Operon) and a FAMlabeled probe (Roche Applied Science Universal Probe Library probe no. 41). No known SNPs overlapped with primer or probe sequences (Supplementary Table 5 ). For normalization, we used a predesigned endogenous control assay interrogating PGK1 (Applied Biosystems; catalog number 4333765F, FAMlabeled). Reactions were carried out in triplicate in a 384-well LightCycler 480 (Roche Applied Science) in reaction volumes of 8 µl, with 5 ng of reversetranscribed RNA, 1× Roche LightCycler 480 Probes master mix, 450 nM of each primer and 125 nM of fluorescent probe. Assay efficiencies were determined using twofold serial dilutions of pooled cDNA. Relative expression levels for PBRM1 were calculated using the efficiency-corrected comparative threshold method 28 . We used the sample with the median PBRM1 expression level as calibrator and log 2 -transformed expression levels. One hundred samples were successfully assayed. (As recommended by SMRI, we omitted one case sample because of a known degenerative neurological disorder.) Of the remaining 99 samples (31 with bipolar disorder, 34 with schizophrenia and 33 healthy controls), 97 were from donors of European ancestry. Ninetysix of these samples were successfully genotyped at rs2251219 with standard exonuclease methods (TaqMan, Applied Biosystems). We carried out analysis of variance (Xlstat 6 .0), with diagnosis as the independent variable and relative expression level as the dependent variable. Specific comparisons were performed with the Tukey HSD (Honestly Significant Difference) test. The entire data set has been uploaded to the SMRI data bank.
